Tyra Biosciences to Present at ENDO 2025
Tyra Biosciences, Inc., a pioneering company in the biotechnology sector focused on precision medicine, recently made headlines with the announcement of a late-breaking poster presentation at the Endocrine Society's Annual Meeting, ENDO 2025. The event will be held from July 12-15, 2025, in the vibrant city of San Francisco, California. This presentation is anticipated to draw significant attention from medical and scientific communities due to the promising insights on TYRA-300, Tyra's lead candidate drug.
Poster Presentation Highlights
The featured abstract, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," carries the abstract code SUN-730. Dr. Jacqueline H. Starrett from Tyra Biosciences will be the presenting author, sharing her team's innovative research findings that suggest potential applications for TYRA-300 in addressing skeletal dysplasia associated with FGFR3 mutations. This presentation is scheduled for July 13 from 12:00 PM to 1:30 PM at the ENDOExpo Poster Area, specifically in session P70 focusing on bone and mineral metabolism and rare genetic conditions.
About TYRA-300
TYRA-300 is an investigational, orally administered FGFR3-selective inhibitor designed as a pioneering approach to treating various cancers and skeletal disorders. Utilizing the company’s proprietary SNÅP platform, TYRA-300 aims to offer precise targeting while minimizing toxicities associated with other FGFR inhibitors. The drug has shown interim clinical proof-of-concept in treating metastatic urothelial cancer and is currently advancing through several key Phase 2 clinical trials, including SURF302 for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), BEACH301 focusing on pediatric achondroplasia, and SURF301 for metastatic urothelial cancer.
Clinical Development and Future Perspectives
The ongoing clinical development of TYRA-300 showcases Tyra Biosciences' commitment to addressing significant medical needs across a spectrum of illnesses. By leveraging its advanced drug design platform, the company is poised to meet the challenges presented by genetic resistance mechanisms that frequently undermine existing therapies. With a robust pipeline that includes additional compounds like TYRA-200, an FGFR1/2/3 inhibitor, and TYRA-430, targeting FGFR4/3-biased cancers, the future appears bright for Tyra Biosciences.
Conclusion
Tyra Biosciences continues to solidify its position as a leader in precision medicine, with TYRA-300 at the forefront of its innovations. The upcoming presentation at ENDO 2025 represents not only a platform for sharing groundbreaking research but also an opportunity for the scientific community to engage with potential new treatments that aim to improve patient outcomes in challenging conditions associated with FGFR pathways. For those interested in following the developments from this year’s ENDO conference, more detailed information will be available post-conference on the Tyra Biosciences website.
For insights into the broader scope of Tyra's projects and their commitment to advancing personalized medicine, you can visit
Tyra Biosciences Website and connect through their LinkedIn.